MedTrace Logo

A Phase 1 Clinical Trial of AUR106 in Patients With Relapsed Advanced Malignancies

NCT05861947 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 21

Last updated 2026-04-17

No results posted yet for this study

Summary

A Phase I, Open Label, Dose-Escalation, First in Human (FIH) Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of AUR106 in Patients with Select Relapsed Advanced Malignancies (JIVAN).

Conditions

Interventions

DRUG

AUR106

Once or twice daily

Sponsors & Collaborators

  • Aurigene Discovery Technologies Limited

    lead INDUSTRY

Principal Investigators

  • Akhil Kumar, MD · Head Clinical Development

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-08-26
Primary Completion
2026-02-10
Completion
2026-02-10
FDA Drug
Yes

Countries

  • India

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05861947 on ClinicalTrials.gov